| Autor: |
L. F. A. Wessels, Amina Zoubeidi, Wilbert Zwart, Simon Linder, Suzan Stelloo, Nicholas Lack, M. Alkemade, Joyce Sanders, J. De Jong, A.M. Bergman, Marlous Hoogstraat, Elise Bekers, H.A. De Barros, Claudia Giambartolomei, Ji Hae Seo, Karianne Schuurman, Yongsoo Kim, L. M. Butler, Bogdan Pasaniuc, Roel J.C. Kluin, Mathew Freedman, H.G. Van Der Poel |
| Rok vydání: |
2021 |
| Předmět: |
|
| DOI: |
10.1101/2021.11.02.21265806 |
| Popis: |
In prostate cancer, androgen receptor (AR)-targeting agents are very effective in various stages of the disease. However, therapy resistance inevitably occurs and little is known about how tumor cells adapt to bypass AR suppression. Here, we performed integrative multi-omics analyses on tissues isolated before and after 3 months of AR-targeting enzalutamide monotherapy from high-risk prostate cancer patients enrolled in a neoadjuvant clinical trial. Transcriptomic analyses demonstrated that AR inhibition drove tumors towards a neuroendocrine-like disease state. In addition, epigenomic profiling revealed massive enzalutamide-induced reprogramming of pioneer factor FOXA1 – from inactive chromatin binding sites towards active cis-regulatory elements that dictate pro-survival signals. Notably, treatment-induced FOXA1 sites were enriched for the circadian rhythm core component ARNTL. Post-treatment ARNTL levels associated with poor outcome, and ARNTL suppression decreased cell growth in vitro. Our data highlight a remarkable cistromic plasticity of FOXA1 following AR-targeted therapy, and revealed an acquired dependency on circadian regulator ARNTL, a novel candidate therapeutic target.SignificanceUnderstanding how prostate cancer cells adapt to AR-targeted interventions is critical for identifying novel drug targets to improve the clinical management of treatment-resistant disease. Our study revealed an enzalutamide-induced epigenetic plasticity towards pro-survival signaling, and uncovered circadian regulator ARNTL as an acquired vulnerability after AR inhibition, presenting a novel clinical lead for therapeutic development. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
